文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-C2Am:靶向检测体内肿瘤细胞死亡的PET显像剂

18F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography.
PubMed 文献 · EJNMMI Res · 2020-12-09

本研究开发了靶向磷脂酰丝氨酸结合蛋白C2Am的18F标记衍生物18F-C2Am,用于PET显像体内肿瘤细胞死亡。在小鼠人肿瘤异种移植模型中,TRAILR2激动剂或常规化疗后2小时,18F-C2Am的肿瘤/肌肉比值分别达6.1±2.1(结直肠癌)和10.7±2.4(乳腺癌),且示踪剂摄取与CC3、TUNEL等细胞死亡标志物显著相关。结果表明18F-C2Am可快速评估肿瘤治疗反应,具有临床转化潜力。

要点

  • 18F-C2Am经肾脏快速清除,给药后2小时脾、肝、小肠、骨和肾滞留低。
  • TRAILR2激动剂治疗后2小时,结直肠癌和乳腺癌模型的肿瘤/肌肉比值分别为6.1±2.1和10.7±2.4。
  • 示踪剂摄取与CC3(Pearson R=0.733,P=0.0005)和TUNEL(Pearson R=0.532,P=0.023)显著相关。

核心结论

  • 18F-C2Am因血液快速清除和低肾脏滞留,可在治疗过程中显像肿瘤内细胞死亡的空间分布,快速评估肿瘤治疗反应。
  • 18F-C2Am具有用于临床评估肿瘤早期治疗反应的潜力。

研究设计与样本

  • 本研究开发了N-(5-[18F]氟戊基)马来酰亚胺的一锅两步自动化合成(合成时间60分钟,放射化学纯度>98%),并在室温下30分钟内用于标记C2Am的单一半胱氨酸残基。
  • 在体外评估18F-C2Am与凋亡和坏死肿瘤细胞的结合,并在接受TRAILR2激动剂或常规化疗的人肿瘤异种移植小鼠中进行动态PET和生物分布测量。
  • 通过将探针结合与显像后立即获取的肿瘤切片中细胞死亡的组织学标志物进行相关性分析,验证C2Am对肿瘤细胞死亡的检测。

主要发现

  • 18F-C2Am显示有利的生物分布特征,给药后2小时主要经肾脏清除,脾、肝、小肠、骨和肾滞留极少。
  • TRAILR2激动剂治疗后2小时内,18F-C2Am在结直肠癌和乳腺癌模型中的肿瘤/肌肉比值分别为6.1±2.1和10.7±2.4。
  • 治疗后乳腺癌和结直肠癌异种移植瘤的细胞死亡水平(CC3阳性率)分别为12.9-58.8%和11.3-79.7%。
  • 总体而言,CC3阳性率增加20%使治疗后/治疗前肿瘤对比度增加一个单位。
  • 给药后2小时的治疗后示踪剂摄取与细胞死亡组织学标志物显著相关(CC3:Pearson R=0.733,P=0.0005;TUNEL:Pearson R=0.532,P=0.023)。

关键数值与推荐

  • 18F-C2Am合成时间60分钟,放射化学纯度>98%,标记C2Am单一半胱氨酸残基在室温下30分钟内完成。
  • 给药后2小时,结直肠癌和乳腺癌模型的肿瘤/肌肉比值分别为6.1±2.1和10.7±2.4。
  • 治疗后乳腺癌和结直肠癌异种移植瘤的CC3阳性率分别为12.9-58.8%和11.3-79.7%。
  • CC3阳性率增加20%对应治疗后/治疗前肿瘤对比度增加一个单位。
  • 示踪剂摄取与CC3(Pearson R=0.733,P=0.0005)和TUNEL(Pearson R=0.532,P=0.023)显著相关。

临床怎么用

  • 18F-C2Am PET可在治疗开始后2小时内显像肿瘤细胞死亡的空间分布,有望用于早期评估肿瘤治疗反应。
  • 示踪剂经肾脏快速清除且正常组织滞留低,有利于在治疗过程中重复显像监测疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Trialing novel cancer therapies in the clinic would benefit from imaging agents that can detect early evidence of treatment response. The timing, extent and distribution of cell death in tumors following treatment can give an indication of outcome. We describe here an 18F-labeled derivative of a phosphatidylserine-binding protein, the C2A domain of Synaptotagmin-I (C2Am), for imaging tumor cell death in vivo using PET. METHODS: A one-pot, two-step automated synthesis of N-(5-[18F]fluoropentyl)maleimide (60 min synthesis time, > 98% radiochemical purity) has been developed, which was used to label the single cysteine residue in C2Am within 30 min at room temperature. Binding of 18F-C2Am to apoptotic and necrotic tumor cells was assessed in vitro, and also in vivo, by dynamic PET and biodistribution measurements in mice bearing human tumor xenografts treated with a TRAILR2 agonist or with conventional chemotherapy. C2Am detection of tumor cell death was validated by correlation of probe binding with histological markers of cell death in tumor sections obtained immediately after imaging. RESULTS: 18F-C2Am showed a favorable biodistribution profile, with predominantly renal clearance and minimal retention in spleen, liver, small intestine, bone and kidney, at 2 h following probe administration. 18F-C2Am generated tumor-to-muscle (T/m) ratios of 6.1 ± 2.1 and 10.7 ± 2.4 within 2 h of probe administration in colorectal and breast tumor models, respectively, following treatment with the TRAILR2 agonist. The levels of cell death (CC3 positivity) following treatment were 12.9-58.8% and 11.3-79.7% in the breast and colorectal xenografts, respectively. Overall, a 20% increase in CC3 positivity generated a one unit increase in the post/pre-treatment tumor contrast. Significant correlations were found between tracer uptake post-treatment, at 2 h post-probe administration, and histological markers of cell death (CC3: Pearson R = 0.733, P = 0.0005; TUNEL: Pearson R = 0.532, P = 0.023). CONCLUSION: The rapid clearance of 18F-C2Am from the blood pool and low kidney retention allowed the spatial distribution of cell death in a tumor to be imaged during the course of therapy, providing a rapid assessment of tumor treatment response. 18F-C2Am has the potential to be used in the clinic to assess early treatment response in tumors.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Bulat F, Hesse F, Hu DE, et al. 18F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography. EJNMMI Res. 2020. PMID: 33296043. doi:10.1186/s13550-020-00738-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。